<DOC>
	<DOCNO>NCT01881204</DOCNO>
	<brief_summary>The primary objective clinical trial test hesperidin without CALCILOCK® bone resorption suppress effect postmenopausal woman . The secondary objective comparison 41Ca technology classical biomarker evaluate bone resorption .</brief_summary>
	<brief_title>Hesperidin Bone Health Postmenopausal Women</brief_title>
	<detailed_description>Subjects participate four phase study : Baseline 50 day three intervention phase include 50 day receive product follow 50 day recovery . The total duration study 350 day . If participant previously label 41Ca , 150 day period add study . Hesperidin ( 552mg ) Calcilock® ( amount per day : Calcium : 684 mg ; Phosphorus : 282mg ; Magnesium : 102mg ; Zinc : 2.86mg ; Vitamin C : 20 mg ; Vitamin K1 : 28µg ; Vitamin D : 1.86µg ) administer form cooky ( biscuit ) .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<criteria>Women least 4 year postmenopausal Medications affect bone resorption</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Hesperidin</keyword>
	<keyword>Osteoporosis</keyword>
	<keyword>Bone Loss</keyword>
</DOC>